Carcinoembryonic Antigen Market Report 2026

The carcinoembryonic antigen market size has grown rapidly in recent years. It will grow from $1.38 billion in 2025 to $1.56 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to increasing cancer prevalence rates, expansion of diagnostic laboratory infrastructure, growing use of blood-based biomarkers, rising awareness of cancer monitoring tools, advancements in immunoassay technologies.

The carcinoembryonic antigen market size is expected to see rapid growth in the next few years. It will grow to $2.44 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing adoption of precision oncology, rising demand for non-invasive cancer diagnostics, expansion of molecular testing capabilities, growing investments in oncology research, increasing focus on treatment response monitoring. Major trends in the forecast period include increasing adoption of tumor marker testing, rising use of cea in cancer monitoring, growing integration of molecular and serology diagnostics, expansion of personalized oncology diagnostics, enhanced focus on early cancer detection.

The rising incidence of cancer is expected to drive the growth of the carcinoembryonic antigen market in the coming years. Cancer is a disease marked by the uncontrolled proliferation and spread of abnormal cells. The increasing prevalence of cancer is attributed to factors such as lifestyle habits, environmental pollution, genetic predisposition, and an aging population. Carcinoembryonic antigen (CEA) is a tumor marker used in cancer to track disease progression and assess treatment effectiveness. For example, in February 2024, the World Health Organization (WHO), a US-based intergovernmental organization, projected approximately 35 million new cancer cases by 2050, representing a 77% rise from the estimated 20 million cases in 2022. Consequently, the growing incidence of cancer is fueling the expansion of the carcinoembryonic antigen market.

Key companies in the carcinoembryonic antigen market are concentrating on developing innovative solutions, such as investigational cell therapy, to enhance targeted treatment efficacy, improve patient outcomes, and advance personalized cancer care. Investigational cell therapy involves experimental treatments using modified or engineered living cells to target diseases and is currently under clinical investigation. For instance, in March 2024, A2 Biotherapeutics Inc., a US-based biotechnology company, received FDA Orphan Drug Designation for its investigational cell therapy, A2B530, which targets a specific subset of colorectal cancer patients. This designation applies to germline heterozygous HLA-A02(+) patients whose colorectal tumors express carcinoembryonic antigen (CEA) but have lost HLA-A02 expression, a group with significant unmet medical needs and limited treatment options.

In December 2023, Danaher Corporation, a US-based life sciences and diagnostics innovator, acquired Abcam Limited for an undisclosed sum. The acquisition aimed to strengthen Danaher's capabilities and expand its market presence, benefiting both the company and its shareholders. Abcam Limited is a US-based manufacturer, distributor, and seller of protein research tools, including recombinant human carcinoembryonic antigen (CEA) protein.

Major companies operating in the carcinoembryonic antigen market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific Inc., Danaher Corporation, bioMérieux SA, Sysmex Corporation, Randox Laboratories Ltd., Snibe Diagnostic, Mindray Bio-Medical Electronics, DiaSorin S.p.A., Tosoh Corporation, Fujirebio, Merck KGaA, Abcam plc, RayBiotech Inc., Boster Biological Technology, Hytest Ltd., Prospec-Tany Technogene Ltd, Creative Diagnostics.

North America was the largest region in the carcinoembryonic antigen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoembryonic antigen market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the carcinoembryonic antigen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the carcinoembryonic antigen market by increasing costs of imported reagents, diagnostic kits, laboratory instruments, and analytical software used in cancer testing and monitoring. Diagnostic centers and hospitals in North America and Europe are most affected due to reliance on imported testing consumables, while Asia-Pacific faces cost pressures in diagnostic manufacturing. These tariffs raise operational expenses and may slow test adoption. However, they are also driving local production of diagnostic reagents, regional manufacturing of test kits, and innovation in cost-effective cancer biomarker solutions.

The carcinoembryonic antigen market research report is one of a series of new reports that provides carcinoembryonic antigen market statistics, including carcinoembryonic antigen industry global market size, regional shares, competitors with a carcinoembryonic antigen market share, detailed carcinoembryonic antigen market segments, market trends and opportunities, and any further data you may need to thrive in the carcinoembryonic antigen industry. This carcinoembryonic antigen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Carcinoembryonic antigen (CEA) is a glycoprotein that plays a role in cell adhesion and is commonly present in embryonic tissues as well as in various carcinomas. In clinical practice, CEA is mainly used as a tumor marker to support the diagnosis, monitoring, and management of cancer, especially colorectal cancer. It aids in evaluating the effectiveness of cancer treatments and is used to monitor patients after treatment for potential cancer recurrence.

The primary test types for carcinoembryonic antigen are molecular tests and serology tests. Molecular tests for CEA involve detecting and analyzing genetic material, such as DNA or RNA, to determine CEA levels. It is applicable to both males and females. Its various applications include gastrointestinal cancer, colorectal cancer, pancreatic cancer, breast cancer, lung cancer, thyroid cancer, ovarian cancer, and others, for end users such as hospitals, diagnostic centers, cancer centers, and research and academic institutes.

The carcinoembryonic antigen market consists of sales of diagnostic kits or assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.